Tumor cell recognition ligands on malignant cells

Tumor cell recognition ligands on malignant cells represent a broad class of molecules expressed on the surface of cancerous cells that facilitate their identification by the immune system or therapeutic agents (Source: National Cancer Institute). These ligands include tumor-associated antigens (TAAs), which are overexpressed in tumors but may exist in normal tissues, and tumor-specific antigens (TSAs) or neoantigens, which arise from somatic mutations and are unique to the malignancy (Source: Nature Reviews Cancer). In a physiological context, these molecules often function in cell signaling, adhesion, or immune evasion, but their primary clinical relevance lies in their role as docking sites for targeted therapies (Source: PubMed). Therapeutic strategies such as monoclonal antibodies, antibody-drug conjugates (ADCs), and chimeric antigen receptor (CAR) T-cell therapies are designed to bind these ligands with high affinity to induce cell death (Source: NIH). For example, ligands like HER2 or CD20 are classic targets for drugs like trastuzumab and rituximab, respectively (Source: FDA). However, the heterogeneity of ligand expression across different tumor types and the potential for on-target, off-tumor toxicity remain significant challenges in drug development (Source: Journal of Clinical Oncology). Because this term describes a functional category rather than a single protein or receptor, it serves as an umbrella term for numerous distinct molecular targets in oncology. Monitoring the expression of these ligands through immunohistochemistry or flow cytometry is essential for patient stratification and predicting treatment efficacy (Source: StatPearls).

Other names

Tumor-associated antigensTumor-specific antigensCancer cell surface markersNeoantigensTumor-associated molecular patternsTumor recognition molecules

These ligands serve as binding sites for monoclonal antibodies, checkpoint inhibitors, and chimeric antigen receptor (CAR) T-cells to facilitate the targeted destruction of malignant cells by the immune system or cytotoxic payloads (Source: NIH).